RI-MUHC researchers discover new path to stop the spread of cancer

Findings will immediately improve the lives of patients with colon metastasis liver cancer and could lead to more personalized treatment options

Investigators from the Research Institute of the McGill University Health Centre (RI-MUHC), and the Institute of Cancer Research, London (UK), have discovered that some cancer cells can draw blood from existing mature blood vessels allowing them to continue to spread. These findings, published in the journal Nature Medicine, will immediately improve the lives and prognosis of patients with colon cancer, which has metastasized to the liver. The team of researchers is continuing its efforts to better understand the mechanisms behind this discovery in order to develop new targeted therapies aimed at stopping the cancer from spreading.

Cancers are often managed by surgical removal of the tumour. However, as many as half the patients who undergo this procedure to treat colon cancer will develop liver metastasis. Metastasis occurs when cancer cells break away from the primary tumour site and enter the bloodstream, spreading to other parts of the body. It is usually this recurrence of cancer that is fatal for patients.

Dr. Metrakos

Dr. Metrakos

"Metastatic cancer is harder to treat than primary cancer – about 80 per cent of patients diagnosed with colon cancer that metastasizes to the liver are inoperable,” explains Dr. Peter Metrakos, lead author of the study and director of the Multi-Organ Transplant Program and of Hepatopancreatobiliary Surgery. “Chemotherapy has been able to prolong the lives of these patients, but it has not been able to provide a cure. If we can stop the metastasis, we have a better chance of curing patients." 

In an attempt to stop metastatic growth, scientists have focused on angiogenesis – a well-known mechanism by which cancer cells generate new blood vessels in order to grow. In the last decade, researchers have developed drugs to target this process. It seemed obvious that if you block the ability of the tumour to obtain blood – its oxygen and nutrients – you would be able to slow the tumour growth, if not kill it completely. Surprisingly, these drugs, called anti-angiogenic treatments, have succeeded in slowing the growth of some cancers, but they have not successfully increased patient survival.

"We were treating all patients as if they were generating new blood vessels, but our research has revealed that roughly 40-45 per cent of tumours derive their blood supplies from new blood vessels, and another 40-45 per cent derive their blood supplies by co-opting existing blood vessels of the liver to draw their blood, which explains why existing therapies that target new blood vessels are not working as well as predicted,” says Dr. Metrakos. “We thought tumours always generated the growth of new blood vessels but in some cases what they are doing is a little sneakier: the cancer cells surround the existing blood vessels of the liver to draw their blood supply. We need to select our patients based on how their cancers obtain their blood supply and stratify them for the right treatment, essentially personalizing medicine.”

Dr. Metrakos’s team has also done some preliminary work on other solid tumours. More research is needed, but the initial data show that the same observations of access to blood supply could be true in other tumours such as brain and lung cancer, renal cell carcinoma and many others.

 

About the study

The study, "Vessel co–option mediates resistance to anti–angiogenic therapy in liver metastases" was co-authored by Sophia Frentzas, Eve Simoneau, Victoria L. Bridgeman, Peter B. Vermeulen, Shane Foo, Eleftherios Kostaras, Mark Nathan, Andrew Wotherspoon, Zu–hua Gao, Yu Shi, Gert Van den Eynden, Frances Daley, Clare Peckitt, Xianming Tan, Ayat Salman, Anthoula Lazaris, Patrycja Gazinska, Tracy J. Berg, Zak Eltahir, Laila Ritsma, Jacco Van, Rheenen, Alla Khashper, Gina Brown, Hanna Nystrom, Malin Sund, Steven Van Laere, Evelyne Loyer, Luc Dirix, David Cunningham, Peter Metrakos, Andrew R. Reynolds.

 

About the RI-MUHC

The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,300 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Québec – Santé (FRQS). rimuhc.ca 

 

About the Cancer Research Program of the RI-MUHC

The Cancer Research Program (CRP) of the RI-MUHC is comprised of 30 researchers, 10 which are active cancer care clinicians with a collective expertise in basic and translational science.  Our Program principal investigators currently supervise 151 trainees enrolled in several departments at McGill University.


Housed at the new state-of-the-art facilities at the Glen Campus in Montreal, the CRP's greatest strengths are their large bio banks of patient tumor and blood samples. The knowledge and data gathered from these tissues are used by national and international collaborators.